Advertisement

Topics

Sage Therapeutics Announces Brexanolone Hits Primary Endpoints in Both Clinical Trials in Postpartum Depression

14:00 EST 13 Nov 2017 | Drug Discovery Development

Brexanolone was generally well tolerated and showed a similar safety profile as seen in earlier studies.
Contributed Author: 
Sage Therapeutics

Original Article: Sage Therapeutics Announces Brexanolone Hits Primary Endpoints in Both Clinical Trials in Postpartum Depression

NEXT ARTICLE

More From BioPortfolio on "Sage Therapeutics Announces Brexanolone Hits Primary Endpoints in Both Clinical Trials in Postpartum Depression"

Advertisement
Quick Search
Advertisement
Advertisement